Today: 10 March 2026
Browse Category

Earnings Reports 10 January 2026

Samsung Electronics stock clings to 139,000 won after record profit guide — what matters before Jan 29

Samsung Electronics stock clings to 139,000 won after record profit guide — what matters before Jan 29

Samsung Electronics shares closed Friday at 139,000 won, up 0.1%. The company forecast Q4 operating profit near 20 trillion won, a sharp jump from 12.17 trillion won in Q3. Investors await the Jan. 29 earnings call for details on memory and margin pressures. DRAM prices surged over 30% quarter-on-quarter, fueling expectations for further gains.
Broadcom stock jumps after Mizuho lifts target; CPI week sets up next test for AVGO

Broadcom stock jumps after Mizuho lifts target; CPI week sets up next test for AVGO

Broadcom shares jumped 3.7% to $344.97 Friday, lifting the PHLX Semiconductor Index to a record. Mizuho raised its price target on Broadcom to $480, citing “attractive valuations.” Cathie Wood’s ARK Invest bought 31,573 shares, while Broadcom’s legal chief sold 30,000 shares. The stock remains 17% below its 52-week high after a December warning on profit margins.
Netflix stock slips as Paramount challenges Warner deal; CPI and earnings are next

Netflix stock slips as Paramount challenges Warner deal; CPI and earnings are next

Paramount Skydance reaffirmed its $108.4 billion bid for Warner Bros. Discovery, topping Netflix’s $72 billion offer. Netflix shares fell 1.2% to $89.46. Netflix co-CEO Greg Peters received 207,420 shares as performance-based stock units vested. Investors await U.S. inflation data Jan. 13 and Netflix’s fourth-quarter earnings Jan. 20.
Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research stock jumps on Mizuho target hike as chip-tool rally sets up next earnings test

Lam Research shares surged 8.7% to $218.36 Friday after Mizuho raised its price target and the PHLX chip index hit a record. Heavy trading snapped a two-day slide for Lam, which will report earnings Jan. 28. Applied Materials and KLA also posted strong gains. Traders are watching next week’s U.S. inflation data and the Fed’s policy meeting for signals on rate cuts.
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio filed a motion to dismiss part of GSK’s claim in a Delaware court dispute over royalties from cancer drug Jemperli. The court is expected to hear the motion by early March, with trial set for July. GSK ADRs closed up 0.3% at $50.39 in New York; London shares slipped 0.26% to 1,886 pence. Investors await GSK’s Jan. 13 conference appearance and Feb. 4 results.
Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd stock: Feb. 5 results date is set — here’s what traders watch next

Keppel Ltd will release its second-half and full-year 2025 results on Feb. 5, after three Keppel-sponsored REITs report from Jan. 30. Keppel shares closed Friday down 0.7% at S$10.47, trading near a 52-week high. About 2.06 million shares changed hands, with S$10.46 as support and S$10.56 as resistance. All financial releases will be made before market open, the company said.
South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

South32 shares closed up 1.1% at A$3.85, just below their 2026 high, after the miner released its 2026 calendar and set Feb. 12 for half-year results. The company confirmed a March 5 ex-dividend date and flagged a $60 million cost for the Mozal smelter shutdown in Mozambique. The S&P/ASX 200 slipped 0.03% as Rio Tinto fell 6.2%. Glencore shares surged over 10% on takeover talks with Rio Tinto.
Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson stock: TrumpRx drug discounts win tariff waiver as earnings loom

Johnson & Johnson reached a deal with the Trump administration to cut U.S. drug prices and won exemptions from tariffs on its pharmaceuticals. The company will sell medicines at discounted rates through TrumpRx.gov and announced two new U.S. manufacturing sites. J&J stock closed down 0.7% at $204.39. Terms of the agreement remain confidential.
1 124 125 126 127 128 227
Go toTop